The use of a proposed updated EARL harmonization of F-FDG PET-CT in patients with lymphoma yields significant differences in Deauville score compared with current EARL recommendations.

BACKGROUND

The Deauville score (DS) is a clinical tool, based on the comparison between lesion and reference organ uptake of F-fluorodeoxyglucose (FDG), used to stratify patients with lymphoma into categories reflecting their disease status. With a plethora of positron emission tomography with computed tomography (PET-CT) hard- and software algorithms, standard uptake value (SUV) in lesions and reference organs may differ which affects DS classification and therefore medical treatment. The EANM Research Ltd. (EARL) harmonization program from the European Association of Nuclear Medicine (EANM) partly mitigates this issue, but local preferences are common in clinical practice. We have investigated the discordance in DS calculated from patients with lymphoma referred for F-FDG PET-CT reconstructed with three different algorithms: the newly introduced block-sequential regularization expectation-maximization algorithm commercially sold as Q. Clear (QC, GE Healthcare, Milwaukee, WI, USA), compliant with the newly proposed updated EARL recommendations, and two settings compliant with the current EARL recommendations (EARL and EARL, representing the lower and upper limit of the EARL recommendations).

METHODS

Fifty-two patients with non-Hodgkin and Hodgkin lymphoma were included (18 females and 34 males). Segmentation of mediastinal blood pool and liver were semi-automatically performed, whereas segmentation of lesions was done manually. From these segmentations, SUV and SUV were obtained and DS calculated.

RESULTS

There was a significant difference in DS between the QC algorithm and EARL/EARL (p < 0.0001 for both) but not between EARL and EARL (p = 0.102) when SUV was used. For SUV, there was a significant difference between QC and EARL (p = 0.001), but not for QC vs EARL (p = 0.071) or EARL vs EARL (p = 0.102). Five non-responders (DS 4-5) for QC were classified as responders (DS 1-3) when EARL/EARL was used, both when SUV and SUV were investigated.

CONCLUSION

Using the proposed updated EARL recommendations compared with the current recommendations will significantly change DS classification. In select cases, the discordance would affect the choice of medical treatment. Specifically, the current EARL recommendations were more often prone to classify patients as responders.